Drug
SCTB35 injection
SCTB35 injection is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(25%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_3
2
50%
Phase Distribution
2
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 3Large-scale testing
2(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 32 (50.0%)
Trials by Status
not_yet_recruiting375%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
not_yet_recruitingphase_3
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT07570823
not_yet_recruitingphase_3
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT07562022
recruitingphase_1
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042
not_yet_recruitingphase_1
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
NCT06318884
Clinical Trials (4)
Showing 4 of 4 trials
NCT07570823Phase 3
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT07562022Phase 3
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
NCT06841042Phase 1
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06318884Phase 1
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4